WHY IS THIS STUDY IMPORTANT?

Irritable Bowel Syndrome (IBS) affects around 11% of the global population and, in Australia, as many as 1 in 5 Australians will experience symptoms of IBS in their lifetime. IBS is a functional disorder, with symptoms including abdominal pain, bloating, gas, nausea and alternating constipation and diarrhoea.

Current treatment options for IBS and IBD are limited due to the complex pathophysiology of these conditions and as such, there is a severe unmet clinical need for products that can treat each of these primary underlying factors, and induce and maintain remission in patients.

WHO IS INVOLVED?

Anatara Lifesciences (ASX:ANR) is a specialist life sciences company with expertise in developing products for animal and human health. Anatara specialise in developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need.

ABOUT THIS RESEARCH STUDY

Anatara's Gastrointestinal Reprogramming Product (GaRP) is a microbiome-targeted multi- component dietary supplement that has been designed to address the primary underlying factors associated with chronic gastrointestinal conditions such as IBS and inflammatory bowel disease (IBD).

The starting dose of active ingredients was determined based on in-house non-clinical research and extensive review of published clinical and market data for the component actives.

FOR MORE INFORMATION SCAN THE QR CODE OR VISIT

EVRIMA.COM.AU

SCAN ME

IRRITABLE BOWEL SYNDROME CLINICAL STUDY

Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS patients:
A randomized, double-blind, placebo-controlled virtual clinical trial.

powered by evrima

WHO CAN PARTICIPATE



- Male or female, 18 to 65 years old
- Have IBS
- Have a body mass index (BMI) between 18 - 39

WHAT IS INVOLVED?

- **12 Weeks** study period done mainly **online**
  - weekly questionnaires
  - daily diary
- **3 Site Out-patient visits**
  - screening visit
  - two follow up visits

For all study participants, there will be:

- **Study-related medical care at no cost**, you may gain access to potential new research treatments, before they may be widely available
- **A gut microbiome report** for all participants who complete the study. This unique report will allow you to review personalised, science-based information so you can understand your gut microbiome
- **No overnight** stays
- **Financial compensation** for your participation in this study

WHO CANNOT PARTICIPATE?

- Anyone who currently has, or has a history of inflammatory bowel disease or any other diagnosed disease with abdominal symptoms that can resemble IBS
- Anyone who has used systemic steroids or antibiotics within the past month

Further eligibility criteria will be reviewed at screening.